SynthesisWorld journal of surgical oncology2025
Prognostic and clinicopathological value of fibrinogen-to-albumin ratio in patients with esophageal cancer: a meta-analysis.
Synthesis in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFibrinogen-to-albumin ratio (FAR) has been widely examined for its prognostic value in esophageal cancer (EC), although findings across studies have been inconsistent. This meta-analysis aimed to assess the predictive role of FAR in EC.
methodsA comprehensive search was conducted across Web of Science, Embase, PubMed, and Cochrane Library. The prognostic value of FAR in EC was assessed by pooling hazard ratios (HRs) and 95% confidence intervals (CIs). Additionally, the correlation between FAR and clinicopathological features of EC was evaluated using pooled odds ratios (ORs) and 95%CIs.
resultsA total of six studies involving 2,616 patients were included. The analysis revealed that a high FAR was significantly associated with poor overall survival (OS) in EC (HR = 1.98, 95%CI = 1.48-2.65, p < 0.001). Furthermore, elevated FAR correlated significantly with male sex (OR = 1.38, 95%CI = 1.09-1.74, p = 0.007), T3-T4 stages (OR = 2.36, 95%CI = 1.93-2.87, p < 0.001), N1-N3 stages (OR = 1.58, 95%CI = 1.32-1.91, p < 0.001), TNM III-IV stages (OR = 2.68, 95%CI = 1.52-4.73, p = 0.001), and tumor length > 3 cm (OR = 2.36, 95%CI = 1.15-4.87, p = 0.020). However, FAR showed no significant association with age (OR = 0.87, 95%CI = 0.48-1.60, p = 0.660), tumor location (OR = 0.98, 95%CI = 0.77-1.25, p = 0.886), or tumor differentiation (OR = 1.09, 95%CI = 0.76-1.56, p = 0.634).
conclusionThis meta-analysis highlights that an elevated FAR is a strong prognostic indicator of poor OS in patients with EC. Moreover, high FAR is significantly associated with clinical features indicative of tumor progression and metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.